Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838840 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL14493662 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL14433714 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL1058665 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL13589979 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL6865696 | 0.81 | POLB (0.68) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL1788313 | 0.79 | POLB (0.66) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL23406969 | 0.78 | POLB (0.64) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL7588383 | 0.78 | POLB (0.64) | POLBALDH1A1TSHRLMNAGAA | |
| SCHEMBL5811871 | 0.78 | POLB (0.69) | POLBALDH1A1TSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024339-B1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI SA (FR) | 2013-04-10 | — | — | EP | disclosed |
| US-7709494-B2 | for lowering blood glucose, treating diabetes, or increasing insulin release, hyperglycemia; (1S,3R)-3-(4,5-Diphenylpyrimidin-2-yloxymethyl)cyclohexanecarboxylic acid | SANOFI-AVENTIS (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090149486-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
| EP-2024339-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007131619-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149486-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SLC5A1, SLC5A2, DPP4 | POLB 2820/4885ALDH1A1 726/4885TSHR 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.